Product News

Share this article:

GlaxoSmithKline agreed to sell US commercial rights for Wellbutrin XL, an antidepressant, to Biovail Corp. for $510 million, according to a Bloomberg report. Wellbutrin's patent expired over two years ago. GSK will retain rights to the drug outside the US.

 

Rockville, MD-based biotech Vanda Pharmaceuticals secured an FDA approval for its first product, a schizophrenia treatment called Fanapt (iloperidone). The drug will be available in pharmacies later this year, according to a company statement.  

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.